Authors' objectives: Liposomal bupivacaine (LB) is a drug delivery formulation in which the local anesthetic bupivacaine hydrochloride is encapsulated within multivesicular liposomes to provide slow, sustained release of bupivacaine for postoperative pain relief after single-dose, localized administration. Rationale: Bupivacaine hydrochloride (HCl) analgesia is commonly used in patients undergoing total joint arthroplasty (TJA). LB uses a liposomal delivery technology to prolong bupivacaine's analgesic effect during the first few days after surgery, potentially reducing the need for opioids and other pain medications, and possibly facilitating inpatient rehabilitation. Relevant Questions: How does LB compare with other forms of analgesia for reducing pain and opioid consumption following TJA (i.e., total hip arthroplasty, total knee arthroplasty, and total shoulder arthroplasty)? How does LB compare with other forms of analgesia for with respect to function and rehabilitation outcomes, hospital length of stay, and patient satisfaction following TJA? How does LB compare with other types of analgesia with respect to safety in patients undergoing TJA? Have definitive patient selection criteria for LB been established?

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=53786

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc